JP2019513741A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513741A5
JP2019513741A5 JP2018552693A JP2018552693A JP2019513741A5 JP 2019513741 A5 JP2019513741 A5 JP 2019513741A5 JP 2018552693 A JP2018552693 A JP 2018552693A JP 2018552693 A JP2018552693 A JP 2018552693A JP 2019513741 A5 JP2019513741 A5 JP 2019513741A5
Authority
JP
Japan
Prior art keywords
disease
pharmaceutical composition
compound according
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018552693A
Other languages
English (en)
Japanese (ja)
Other versions
JP7061076B2 (ja
JP2019513741A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/026579 external-priority patent/WO2017177124A1/en
Publication of JP2019513741A publication Critical patent/JP2019513741A/ja
Publication of JP2019513741A5 publication Critical patent/JP2019513741A5/ja
Application granted granted Critical
Publication of JP7061076B2 publication Critical patent/JP7061076B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018552693A 2016-04-07 2017-04-07 アイバカフトール類似体を含有するケイ素原子 Active JP7061076B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662319439P 2016-04-07 2016-04-07
US62/319,439 2016-04-07
PCT/US2017/026579 WO2017177124A1 (en) 2016-04-07 2017-04-07 Silicone atoms containing ivacaftor analogues

Publications (3)

Publication Number Publication Date
JP2019513741A JP2019513741A (ja) 2019-05-30
JP2019513741A5 true JP2019513741A5 (enExample) 2020-05-14
JP7061076B2 JP7061076B2 (ja) 2022-04-27

Family

ID=58549338

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018552693A Active JP7061076B2 (ja) 2016-04-07 2017-04-07 アイバカフトール類似体を含有するケイ素原子

Country Status (16)

Country Link
US (5) US10662207B2 (enExample)
EP (1) EP3440057B1 (enExample)
JP (1) JP7061076B2 (enExample)
KR (1) KR102448404B1 (enExample)
CN (1) CN109563047A (enExample)
AR (1) AR108203A1 (enExample)
AU (1) AU2017248253B2 (enExample)
BR (1) BR112018070747B1 (enExample)
CA (1) CA3019663C (enExample)
IL (1) IL262030B (enExample)
MA (1) MA43775A (enExample)
MX (1) MX386698B (enExample)
NZ (1) NZ746793A (enExample)
SA (1) SA518400164B1 (enExample)
SG (1) SG11201808682XA (enExample)
WO (1) WO2017177124A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3798214B1 (en) 2014-10-06 2022-09-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US10548878B2 (en) 2015-07-24 2020-02-04 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods of increasing CFTR activity
NZ741093A (en) 2015-10-06 2022-12-23 Proteostasis Therapeutics Inc Compounds, compositions, and methods for modulating cftr
BR112018070747B1 (pt) 2016-04-07 2024-01-09 Proteostasis Therapeutics, Inc Átomos de silicone contendo análogos de ivacaftor, composições farmacêuticas e usos terapêuticos
EP3472156B1 (en) 2016-06-21 2023-06-07 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
SG10201913595YA (en) 2016-09-30 2020-02-27 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
MA49235B1 (fr) * 2016-12-09 2021-02-26 Vertex Pharma Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
EP3634402B1 (en) 2017-06-08 2026-01-21 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
JP2020525446A (ja) * 2017-06-21 2020-08-27 ザ・ジョンズ・ホプキンス・ユニバーシティ 常染色体優性多発性嚢胞腎疾患を治療するための嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子
BR112020000941A2 (pt) 2017-07-17 2020-07-21 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
TWI799435B (zh) 2017-08-02 2023-04-21 美商維泰克斯製藥公司 製備化合物之製程
US20210369749A1 (en) * 2017-10-06 2021-12-02 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
IL273831B2 (en) 2017-10-19 2024-10-01 Vertex Pharma Crystalline forms and compositions of cftr modulators
CN111757874B (zh) 2017-12-08 2024-03-08 弗特克斯药品有限公司 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3752510B1 (en) 2018-02-15 2022-12-07 Vertex Pharmaceuticals Incorporated Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
WO2019195739A1 (en) 2018-04-05 2019-10-10 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2020006269A1 (en) 2018-06-27 2020-01-02 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
CN109663129B (zh) * 2019-02-27 2021-05-11 四川大学华西第二医院 扩张型心肌病治疗药物及其应用
TWI848092B (zh) 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
KR20220064366A (ko) 2019-08-14 2022-05-18 버텍스 파마슈티칼스 인코포레이티드 Cftr 조절제의 결정질 형태
CA3188787A1 (en) 2020-08-13 2022-02-17 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
CA3204725A1 (en) 2020-12-10 2022-06-16 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN116425642B (zh) * 2023-04-06 2025-06-10 浙江科聚生物医药有限公司 2-甲氧基-4-氟-5-胺基苯酚的制备方法

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3812225A1 (de) 1988-04-13 1989-10-26 Basf Ag Isoxazol(isothiazol)-5-carbonsaeureamide
CA2201478A1 (en) 1995-08-02 1997-02-13 J. Uriach & Cia S.A. New carboxamides with antifungal activity
ATE243204T1 (de) 1995-08-24 2003-07-15 Basf Ag Isoxazole- und isothiazole-5-carboxamid derivate, deren herstellung und deren verwendung als herbizide
PT957099E (pt) 1998-04-15 2003-02-28 Pfizer Prod Inc Carboxamidas heterociclicas
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
JP4901102B2 (ja) 2002-05-03 2012-03-21 エクセリクシス, インク. プロテインキナーゼモジュレーターおよびその使用方法
AU2004279855A1 (en) 2003-10-08 2005-04-21 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters containing cycloalkyl or pyranyl groups
EP1682127B1 (en) 2003-11-14 2009-07-29 Vertex Pharmaceuticals Incorporated Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
CA2565965A1 (en) 2004-05-06 2006-07-27 Plexxikon, Inc. Pde4b inhibitors and uses therefor
SE0401969D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidine derivatives
US20060100226A1 (en) 2004-09-10 2006-05-11 Sikorski James A 2-Thiopyrimidinones as therapeutic agents
DE102004051277A1 (de) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
JP2006176443A (ja) 2004-12-22 2006-07-06 Shionogi & Co Ltd メラニン凝集ホルモン受容体アンタゴニスト
DE602006018301D1 (de) 2005-06-22 2010-12-30 Pfizer Prod Inc Histamin-3-rezeptorantagonisten
JP4822406B2 (ja) 2005-09-26 2011-11-24 ルネサスエレクトロニクス株式会社 表示制御駆動装置および表示システム
WO2007075896A2 (en) 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
KR101394245B1 (ko) 2005-12-30 2014-05-14 에스케이바이오팜 주식회사 아이속사졸 유도체 및 이의 용도
WO2007086584A1 (ja) 2006-01-30 2007-08-02 Meiji Seika Kaisha, Ltd. 新規FabKおよびFabI/K阻害剤
TW200815351A (en) 2006-05-02 2008-04-01 Astrazeneca Ab Novel compounds
WO2008046072A2 (en) 2006-10-13 2008-04-17 The Board Of Regents Of The University Of Texas System Chemical inducers of neurogenesis
US8193225B2 (en) 2006-10-13 2012-06-05 The Board Of Regents Of The University Of Texas System Isoxazole amides, derivatives and methods of chemical induction of neurogenesis
US7678792B2 (en) 2006-10-20 2010-03-16 Irm Llc Compositions and methods for modulating c-kit and PDGFR receptors
WO2008070739A1 (en) 2006-12-06 2008-06-12 Cytokinetics, Inc. Ksp activators
JP5311075B2 (ja) 2007-06-29 2013-10-09 エスケー バイオファーマスティカルズ カンパニー リミテッド イソキサゾール誘導体を含む、再狭窄の予防及び治療のための医薬組成物
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
US8211927B2 (en) 2007-08-02 2012-07-03 MSD, Oss B.V. 5-phenyl-isoxazole-3-carboxamide derivatives as TRPV1 modulators
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8236838B2 (en) 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US20090318429A1 (en) 2008-04-28 2009-12-24 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives
US20120095002A1 (en) 2009-02-04 2012-04-19 N.V. Organon Isoxazole-5-carboxamide derivatives
BRPI1008974A2 (pt) 2009-03-11 2017-06-06 Kyorin Seiyaku Kk composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3
MX384179B (es) * 2009-03-20 2025-03-14 Vertex Pharma Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quística.
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
IN2012DN00352A (enExample) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
WO2011008931A2 (en) 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
US9212177B2 (en) 2009-08-05 2015-12-15 Versitech Limited Antiviral compounds and methods of making and using thereof
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
US8569899B2 (en) 2009-12-30 2013-10-29 Stmicroelectronics, Inc. Device and method for alignment of vertically stacked wafers and die
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2011133953A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
ES2603032T3 (es) 2010-07-15 2017-02-23 Bayer Intellectual Property Gmbh Compuestos de 3-piridil-heteroarilcarboxamida como pesticidas
DK2684880T3 (en) 2011-03-10 2018-05-22 Daiichi Sankyo Co Ltd DISPIROPYRROLIDINE DERIVATIVES
CA2736441A1 (en) 2011-04-06 2012-10-06 The Regents Of The University Of California Pyrazolylthiazole compounds as .delta.f508-cystic fibrosis transmembrane conductance regulator correctors
PL2709986T3 (pl) 2011-05-18 2017-09-29 Concert Pharmaceuticals Inc. Deuterowane pochodne iwakaftoru
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
CA2842364A1 (en) 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
US9056867B2 (en) 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
US8623860B2 (en) 2011-12-30 2014-01-07 Boehringer Ingelheim International Gmbh Azetidine derivatives, pharmaceutical compositions and uses thereof
JP6138834B2 (ja) 2012-02-16 2017-05-31 ダウ アグロサイエンシィズ エルエルシー スルフィルイミン化合物の製造方法
UA110436C2 (en) 2012-03-06 2015-12-25 Zoetis Llc Antibacterial phenol compounds
WO2013146970A1 (ja) 2012-03-29 2013-10-03 第一三共株式会社 新規キノリン誘導体
ES2713988T3 (es) 2012-08-01 2019-05-24 United Therapeutics Corp Tratamiento de hipertensión arterial pulmonar con células progenitoras endoteliales tratadas con prostaciclina
WO2014045283A1 (en) 2012-09-24 2014-03-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Restoration of the cftr function by splicing modulation
WO2014081821A2 (en) 2012-11-20 2014-05-30 Discoverybiomed, Inc. Small Molecule Bicyclic and Tricyclic CFTR Correctors
AU2013348018A1 (en) 2012-11-20 2015-06-04 Discoverybiomed, Inc. Small molecule CFTR correctors
CN103833630B (zh) * 2012-11-21 2018-11-13 顶点制药(欧洲)有限公司 氘化cftr增效剂
WO2014160478A1 (en) 2013-03-13 2014-10-02 Flatley Discovery Lab Compounds and methods for the treatment of cystic fibrosis
US9783529B2 (en) 2013-03-13 2017-10-10 Flatley Discovery Lab, Llc Pyridazinone compounds and methods for the treatment of cystic fibrosis
CA2903103C (en) 2013-03-15 2020-06-09 Discoverybiomed, Inc. Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders
CA2907260A1 (en) 2013-03-15 2014-09-18 The University Of North Carolina Chapel Hill Correctors acting through msd1 of cftr protein
WO2014176553A1 (en) 2013-04-26 2014-10-30 Vertex Pharmaceuticals Incorporated Correctors acting through msd1 of cftr protein
MX368263B (es) 2013-05-07 2019-09-26 Galapagos Nv Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica.
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
US20160151335A1 (en) 2013-06-26 2016-06-02 Proteostasis Therapeutics, Inc. Methods of modulating cftr activity
WO2015051230A1 (en) 2013-10-04 2015-04-09 Drexel University Novel compositions useful for inhibiting hiv-1 infection and methods using same
EP3116501A1 (en) 2014-03-13 2017-01-18 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
EP3116870A1 (en) 2014-03-13 2017-01-18 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
CA2952862A1 (en) 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
US9855249B2 (en) 2014-10-02 2018-01-02 Flatley Discovery Lab, Llc Isoxazole compounds and methods for the treatment of cystic fibrosis
US10344023B2 (en) 2014-12-23 2019-07-09 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10738011B2 (en) 2014-12-23 2020-08-11 Proteostasis Therapeutics, Inc. Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10392378B2 (en) 2014-12-23 2019-08-27 Proteostasis Therapeutics, Inc. Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA41253A (fr) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
US20180147187A1 (en) 2015-01-12 2018-05-31 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
US10548878B2 (en) 2015-07-24 2020-02-04 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods of increasing CFTR activity
WO2017040606A1 (en) 2015-08-31 2017-03-09 Proteostasis Therapeutics, Inc. Isoxazole derivatives for use in the treatment of pulmonary diseases and disorders
NZ741093A (en) 2015-10-06 2022-12-23 Proteostasis Therapeutics Inc Compounds, compositions, and methods for modulating cftr
EP3393465A1 (en) 2015-12-22 2018-10-31 Proteostasis Therapeutics, Inc. Methods of treating pulmonary diseases and disorders
BR112018070747B1 (pt) 2016-04-07 2024-01-09 Proteostasis Therapeutics, Inc Átomos de silicone contendo análogos de ivacaftor, composições farmacêuticas e usos terapêuticos
EP3455624A1 (en) 2016-05-09 2019-03-20 Proteostasis Therapeutics, Inc. Methods of identifying cftr modulators
EP3472156B1 (en) 2016-06-21 2023-06-07 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity

Similar Documents

Publication Publication Date Title
JP2019513741A5 (enExample)
IL273752B1 (en) Ingredients, compounds and methods for increasing cftr activity
NZ746793A (en) Silicone atoms containing ivacaftor analogues
JP7196217B2 (ja) 重水素化されたcftr増強剤の投与
JP2013508414A5 (enExample)
SI2328618T1 (en) A pharmaceutical composition of N- (2,4-bis (1,1-dimethylethyl) -5-hydroxyphenyl) -1,4-dihyro-4-oxyloquinoline-3-carboxamide and its administration
HRP20210165T1 (hr) Čvrsta disperzija amorfnog oblika (r)-1(2,2-difluorobenzo(d)(1,3)dioksol-5-il)-n-(1-(2,3-dihidroksipropil)-6-fluoro-2-(1-hidroksi-2-metilpropan-2-il)-1h-indol-5-il)-ciklopropankarboksamida
RU2017126232A (ru) Соединения, композиции и способы для повышения активности cftr
JP2011505338A5 (enExample)
JP2013501787A5 (enExample)
JP2011516420A5 (enExample)
SI3091011T1 (en) Modulators of ATP conveyor belt conveyors
RU2018116569A (ru) Соединения, композиции и способы для модуляции cftr
JP2013508407A5 (enExample)
JP2012521361A5 (enExample)
JP2013536231A5 (enExample)
RU2012129206A (ru) Модуляторы атф-связывающих транспортеров
JP2013513617A5 (enExample)
CA3041819A1 (en) Methods of treatment with deuterated cftr potentiators
HRP20160682T1 (hr) Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzojeve kiseline
JP2013245219A5 (enExample)
JP2011513321A5 (enExample)
JP2015511583A5 (enExample)
RU2008122929A (ru) Гетероциклические модуляторы транспортеров атф-связывающей кассеты
US20210052570A1 (en) Methods of treatment with deuterated cftr potentiators